ClinicalTrials.gg
Not yet recruitingNCT07496346Updated Oct 19, 2026

Integration of a Robotic Platform for Clinical Monitoring of Patients With Severe Acquired Brain Injury in High-Intensity Care Units

An interventional study of Robotic platform monitoring system in User Experience, Usability and Acceptability, sponsored by Ernesto Losavio. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Ernesto Losavio · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 19, 2026Start date movedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Frailty is not related exclusively to age, but represents a state of increased biological and clinical vulnerability characterized by reduced functional reserve and greater susceptibility to adverse events, even in response to minor stress factors. In patients with complex conditions, such as severe acquired brain injuries, early detection and prompt treatment of clinical deterioration are essential to reduce the risk of acute readmission, complications, and in-hospital mortality. Many of these events are potentially predictable and preventable, given the presence of appropriate monitoring systems.

Advanced care models, including early warning systems, have been developed to support healthcare professionals in identifying patients at risk by detecting significant changes in physiological parameters. In recent years, technological innovations-particularly in the fields of robotics and telemedicine-have created new opportunities to enhance clinical monitoring, enabling more systematic data collection and timely clinical assessment.

Social assistive robots are emerging as promising tools in healthcare settings. These systems can support clinicians and nurses in routine monitoring activities, help reduce workload, and facilitate more efficient and personalized care. By integrating robotic assistance with digital health platforms, it may be possible to support patient monitoring and clinical workflow, particularly in high-complexity environments such as neurorehabilitation units.

This study focuses on the use of an innovative robotic telemedicine system based on the integration of the MOVER-L prototype with the ROB.IN.CARE platform, owned by Item Oxygen Srl, which purchased the platform from CO-ROBOTICS S.R.L. through the PON SI-ROBOTICS project. The system is designed to support the monitoring of patients' clinical conditions by integrating physiological and clinical data and identifying predefined signs of potential deterioration. It supports healthcare professionals by providing clinical information and automated alerts that prompt healthcare-professional review.

The study is a low-intensity, non-randomized controlled pilot feasibility interventional study conducted in a Neurorehabilitation Unit. Patients with varying levels of clinical severity, classified according to the Glasgow Coma Scale, are enrolled and allocated to one of two groups: a control group receiving standard care and an experimental group monitored using the robotic system in addition to usual care.

The primary objective of the study is to evaluate the feasibility, usability, safety, and reliability of this robotic telemedicine solution in a real clinical setting. In addition, the study assesses its acceptability among both patients and healthcare professionals. These aspects are evaluated using predefined feasibility and technical measures together with validated assessment tools, including the System Usability Scale (SUS) and the Health and Safety Executive Stress Indicator Tool (HSE). The specific role and interpretation of these measures are defined in the study protocol.

The integrated MOVER-L/ROB.IN.CARE system combines robotic assistance with the acquisition and integration of physiological and clinical data through a dedicated software architecture. The platform incorporates algorithms designed to stratify clinical risk and assess patient severity. It utilizes established clinical scoring systems, such as the Modified Early Warning Score (MEWS) for early detection of clinical deterioration, the quick Sequential Organ Failure Assessment (qSOFA) for risk assessment in patients with suspected infection, and the Kidney Disease: Improving Global Outcomes (KDIGO) criteria for the assessment of acute kidney injury.

The present pilot study is intended to characterize the feasibility of integrating the MOVER-L/ROB.IN.CARE system into routine neurorehabilitation practice, including its technical performance, usability, safety, acceptability, and integration into the clinical workflow. The findings are intended to identify implementation requirements and sources of variability and to inform the design of subsequent adequately powered studies evaluating the clinical impact of robotic monitoring.

02

Conditions studied

  • User Experience
  • Usability
  • Acceptability
  • Satisfaction

Browse trials for

Keywords

  • Robotic platform
  • Monitoring system
03

In context

Personal Satisfaction

543 studies on the registry are indexed under Personal Satisfaction; 91 are open to participants now.

This study's planned enrollment of 12 is below the median of 93 across 418 interventional studies indexed under Personal Satisfaction.

Browse Personal Satisfaction studies →

Lead sponsor

Ernesto Losavio is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admission to the Neurorehabilitation Unit
  • Requirement for clinical monitoring and/or sub-intensive care
  • Ability to provide , or availability of a legally authorized representative to provide consent

Exclusion criteria

Exclusion Criteria:

  • No indication for intensive or sub-intensive clinical monitoring
  • Expected hospitalization duration insufficient to complete the study protocol
  • Participation in another clinical study that may interfere with the present study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Participants allocated to the experimental group will receive standard clinical care in addition to monitoring supported by the MOVER-L robotic platform and ROB.IN.CARE software. Robot-assisted monitoring will be performed for approximately 12 hours per day for five consecutive days.

    Device: Robotic platform monitoring system

  • No intervention
    Control Group

    Participants allocated to the control group will receive standard clinical care according to routine clinical practice, including conventional medical and nursing assessments. No robotic monitoring will be performed.

Interventions

  • DeviceRobotic platform monitoring system

    The MOVER-L robotic platform, integrated with the ROB.IN.CARE clinical decision-support software, will support patient monitoring by integrating physiological and clinical data acquired from connected medical devices, dedicated sensors, and clinical assessments. The software will use these data to calculate established clinical scores, including MEWS, qSOFA, and KDIGO, and to characterize the patient's clinical risk status. When predefined clinical thresholds are reached, the system will generate alerts prompting review by healthcare professionals. All alerts will be interpreted within the patient's clinical context, and all diagnostic and therapeutic decisions will remain under the responsibility of the healthcare team.

    Also known as: robotic platform, monitoring system

06

What researchers measure

Primary outcomes

  1. Health and Safety Executive (HSE) Management Standards Indicator Tool

    The Health and Safety Executive (HSE) Management Standards Indicator Tool is a 35-item questionnaire assessing psychosocial working conditions across seven domains: demands, control, managerial support, peer support, relationships, role, and change. In the present pilot study, the HSE Indicator Tool will be used to characterize the work-related organizational context of participating healthcare professionals and will not be interpreted as a measure of change attributable to the 5-day robotic intervention. The questionnaire will be administered once to participating healthcare professionals.

    Time frame: Following exposure to the robotic system, at the end of the 5-day study period.

  2. System Usability Scale (SUS)

    The System Usability Scale (SUS) is a validated 10-item questionnaire used to assess perceived system usability. Each item is rated on a 5-point Likert scale. Scores are calculated according to the standard SUS scoring procedure and transformed to a total score ranging from 0 to 100, with higher scores indicating greater perceived usability. The questionnaire will be administered once to participating healthcare professionals following their exposure to the MOVER-L/ROB.IN.CARE system.

    Time frame: Following exposure to the robotic system, at the end of the 5-day study period.

Secondary outcomes

  1. Oxygen Saturation

    Peripheral oxygen saturation (SpO₂) measured by pulse oximetry (%).

    Time frame: From enrollment to the end of the 5-day study period

  2. Heart Rate

    Heart rate measured in beats per minute (bpm).

    Time frame: From enrollment to the end of the 5-day study period

  3. Systolic Blood Pressure

    Systolic blood pressure measured in millimeters of mercury (mmHg).

    Time frame: From enrollment to the end of the 5-day study period

  4. Body Temperature

    Body temperature measured in degrees Celsius (°C).

    Time frame: From enrollment to the end of the 5-day study period

  5. Respiratory Rate

    Respiratory rate measured in breaths per minute (breaths/min).

    Time frame: From enrollment to the end of the 5-day study period

  6. Level of Consciousness (Glasgow Coma Scale)

    Level of consciousness assessed using the Glasgow Coma Scale (GCS), comprising Eye Opening, Verbal Response, and Motor Response components, with a total score ranging from 3 to 15 when all components are testable. Automated assessment is restricted to GCS $\\geq$ 12, whereas lower or non-testable states require bedside assessment by healthcare professionals.

    Time frame: From enrollment to the end of the 5-day study period

  7. Urine Output

    Urine output expressed in mL/hour. Hourly measurements are obtained from the electronic urinometer and the three most recent hourly measurements are entered into ROB.IN.CARE every 3 hours.

    Time frame: From enrollment to the end of the 5-day study period.

  8. Serum Creatinine

    Serum creatinine concentration measured in mg/dL and used as a component of KDIGO acute kidney injury assessment.

    Time frame: At enrollment and when clinically available during the 5-day study period.

  9. AVPU Level of Consciousness

    Level of consciousness assessed using the Alert, Verbal, Pain, Unresponsive (AVPU) scale.

    Time frame: From enrollment to the end of the 5-day study period.

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Nov 2026, 1 month later.

Of 250 non-industry interventional studies with no phase under Personal Satisfaction, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 1 month is below that.

Counting every sponsor, half of 257 studies reached it within 9 months; a quarter within 3 and three quarters within 21.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Mar 27, 2026
StartEst.
Oct 2026was Aug 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Oct 2026
Oct 19, 2026
Primary outcomes
1 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • ChangedBefore HSE Stress ScaleNow Health and Safety Executive (HSE) Management Standards Indicator ToolTime frame: At the end of treatment (1 week) → Following exposure to the robotic system, at the end of the 5-day study period.
  • Time frameSystem Usability Scale (SUS)At the end of treatment (1 week) → Following exposure to the robotic system, at the end of the 5-day study period.
  • DescriptionSystem Usability Scale (SUS): how it is measured was reworded
Oct 19, 2026
Secondary outcomes
2 edited, 5 time frame changed, 2 added, 2 removed, 1 description edited
What changed in the outcomes
  • EditedDiastolicSystolic Blood PressureTime frame: From enrollment to the end of treatment at 1 week → From enrollment to the end of the 5-day study period
  • EditedHourly Urine OutputTime frame: From enrollment to the end of treatment at 1 week → From enrollment to the end of the 5-day study period.
  • AddedSerum CreatinineTime frame: At enrollment and when clinically available during the 5-day study period.
  • AddedAVPU Level of ConsciousnessTime frame: From enrollment to the end of the 5-day study period.
  • RemovedPulse RateTime frame: From enrollment to the end of treatment at 1 week
  • RemovedLaboratory ParametersTime frame: From enrollment to the end of treatment at 1 week
  • Time frameOxygen SaturationFrom enrollment to the end of treatment at 1 week → From enrollment to the end of the 5-day study period
  • Time frameHeart RateFrom enrollment to the end of treatment at 1 week → From enrollment to the end of the 5-day study period
  • Time frameBody TemperatureFrom enrollment to the end of treatment at 1 week → From enrollment to the end of the 5-day study period
  • Time frameRespiratory RateFrom enrollment to the end of treatment at 1 week → From enrollment to the end of the 5-day study period
  • Time frameLevel of Consciousness (Glasgow Coma Scale)From enrollment to the end of treatment at 1 week → From enrollment to the end of the 5-day study period
  • DescriptionLevel of Consciousness (Glasgow Coma Scale): how it is measured was reworded
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Start date Aug 2026→Oct 2026
    Primary outcomes 1 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • ChangedBefore HSE Stress ScaleNow Health and Safety Executive (HSE) Management Standards Indicator ToolTime frame: At the end of treatment (1 week) → Following exposure to the robotic system, at the end of the 5-day study period.
    • Time frameSystem Usability Scale (SUS)At the end of treatment (1 week) → Following exposure to the robotic system, at the end of the 5-day study period.
    • DescriptionSystem Usability Scale (SUS): how it is measured was reworded
    Secondary outcomes 2 edited, 5 time frame changed, 2 added, 2 removed, 1 description edited
    What changed in the outcomes
    • EditedDiastolicSystolic Blood PressureTime frame: From enrollment to the end of treatment at 1 week → From enrollment to the end of the 5-day study period
    • EditedHourly Urine OutputTime frame: From enrollment to the end of treatment at 1 week → From enrollment to the end of the 5-day study period.
    • AddedSerum CreatinineTime frame: At enrollment and when clinically available during the 5-day study period.
    • AddedAVPU Level of ConsciousnessTime frame: From enrollment to the end of the 5-day study period.
    • RemovedPulse RateTime frame: From enrollment to the end of treatment at 1 week
    • RemovedLaboratory ParametersTime frame: From enrollment to the end of treatment at 1 week
    • Time frameOxygen SaturationFrom enrollment to the end of treatment at 1 week → From enrollment to the end of the 5-day study period
    • Time frameHeart RateFrom enrollment to the end of treatment at 1 week → From enrollment to the end of the 5-day study period
    • Time frameBody TemperatureFrom enrollment to the end of treatment at 1 week → From enrollment to the end of the 5-day study period
    • Time frameRespiratory RateFrom enrollment to the end of treatment at 1 week → From enrollment to the end of the 5-day study period
    • Time frameLevel of Consciousness (Glasgow Coma Scale)From enrollment to the end of treatment at 1 week → From enrollment to the end of the 5-day study period
    • DescriptionLevel of Consciousness (Glasgow Coma Scale): how it is measured was reworded
    + 4 other changes: verification date, description, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07496346
Lead sponsor
Ernesto Losavio
Collaborators
Item Oxygen
Responsible party
Ernesto Losavio (Director of the Neurorehabilitation and Spinal Unit, ICS Maugeri IRCCS Bari, Italy, Istituti Clinici Scientifici Maugeri SpA) — Sponsor-investigator
First posted
Mar 27, 2026
Start date
Oct 2026 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion